Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Breast cancer

T-DXd is effective after T-DM1

Nature Reviews Clinical Oncology volume 20, page 426 (2023)Cite this article

Subjects

The antibody–drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) is a highly effective second-line therapy for patients with metastatic HER2-positive breast cancer. Nonetheless, the activity of this agent in patients with disease progression on trastuzumab emtansine (T-DM1), the previous second-line standard of care, remains unknown. Now, data from the phase III DESTINY-Breast02 trial provide evidence supporting the use of T-DXd in this setting.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    Peter Sidaway

Authors
  1. Peter Sidaway
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Sidaway.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sidaway, P. T-DXd is effective after T-DM1. Nat Rev Clin Oncol 20, 426 (2023). https://doi.org/10.1038/s41571-023-00779-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-023-00779-6

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer